drugset / Trial / NCT04019288
AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase 1/2
Terminated
12 enrolled
M.D. Anderson Cancer Center
Aravive Biologics Inc · collabAstraZeneca · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This trial studies the side effects and best dose of AVB-S6-500 when given together with durvalumab in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that is resistant to platinum therapy or has come back. Immunotherapy with AVB-S6-500 and durvalumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread.
Timeline
- Start
- 2019-12-03
- Primary completion
- 2024-10-24
- Completion
- 2024-10-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Batiraxcept | Protein / enzyme biologic | — | Intravenous |
| Subject | Durvalumab | Monoclonal antibody | — | Intravenous |